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Background: This study retrospectively investigated nutritional status, dietetic intervention and intake in Cystic Fibrosis (CF) patients before and
after lung transplantation (LTX).
Methods: Body Mass Index (BMI), Fat Free Mass Index (FFMI) and nutritional intake were retrieved from 75 out-patients aged 15–53 years.
Patients were seen every 3–4 months during the waiting list time (range 0–81 months) and up to 116 months after LTX. Survival was measured in
months.
Results: The median BMI at baseline was 19.2 kg/m2 (range: 15.3 to 28.4 kg/m2) with 29 patients (39%) below ≤18.5 kg/m2. FFMI (measured in
65 patients) had a median of 15.2 kg/m2 (range: 11.1 to 22.4 kg/m2) with 39 patients (60%) ≤16.7 kg/m2 (men) or ≤14.6 kg/m2 (women).
Median energy intake was 2800 kcal, 239 kcal higher than the estimated energy requirement. However, 8 patients consumed ≥500 kcal less than
recommended. Protein intake was 104 (range 60–187) g or 1.9 g/kg per day. Despite dietetic intervention with oral nutritional supplements (ONS)
(36 patients), tube feeding (12 patients), or both (13 patients), BMI and FFMI hardly improved pre-LTX. LTX was performed in 51 patients (68%);
10 patients died during follow-up, median survival time was 41 months. A BMI ≤ 18.5 kg/m2 was more prevalent in patients who died before
LTX (6/9) or who died after LTX (4/10) than in patients who were still alive on the waiting list (5/15) or who survived LTX (14/41). Results for
FFMI were comparable. From 6–12 months post-LTX, BMI and FFMI markedly improved, especially in underweight patients.
Conclusion: A BMI ≤18.5 kg/m2 and an FFMI ≤16.7 kg/m2 (men) or ≤14.6 kg/m2 (women) appears to impair survival in LTX candidates with
CF. Patients maintained a low body weight before LTX. After LTX weight gain is achieved.
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Lung transplantation (LTX) is an established treatment option
for end-stage lung disease in Cystic Fibrosis (CF) patients [1]. An
optimal nutritional status pre-and post-lung transplant is an
important predictor of survival in CF patients [2,3]. However,
malnutrition is a common problem in patients with CF due to fat
malabsorption and a higher energy expenditure as a result of
inflammation, frequent periods of severe respiratory tract
infections, and increased work of breathing when lung function
declines [4,5]. A good indicator of nutritional status in CFby Elsevier B.V. All rights reserved.
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patients (BMI b 18.5 kg/m2) have a 25% higher risk of
mortality than adult CF patients with a normal weight [7]. On
the other hand, the prevalence of overweight and obesity in CF
patients is increasing, with estimates ranging from 10% in the
UK [8,9] to 18.4% in Canada. This may not be desirable,
because mortality after LTX was shown to be higher in
underweight, overweight, and obese patients (including CF
patients) than in normal-weight patients [10]. A BMI below
18 kg/m2 is often used as a preclusion for LTX [1]. Thus,
keeping the BMI between 18 and 30 kg/m2 before LTX is an
important treatment goal.
Lean body mass or Fat Free Mass (FFM) is another indicator
for nutritional status. It is a measure of muscle mass and
correlates with (inspiratory) muscle function, quality of life [11],
and lung function [12]. Depletion of FFM is strongly associated
with increased mortality while awaiting LTX and with prolonged
post-transplant intensive care unit stays [3]. This means that not
just body weight but also FFM should be monitored in CF
patients to avoid fat accumulation and loss of muscle mass.
Pre- and post-transplant nutrition management is aimed to
maintain or improve nutritional status, in order to meet the criteria
for LTX and optimize survival before and after LTX. Few studies
have investigated nutritional intervention strategies in patients on
the waiting list for lung transplantation [2,13,14]. One study
demonstrated that Percutaneous Endoscopic Gastrostomy (PEG)
feeding may improve body weight before LTX in patients with a
low BMI [2]. Another study showed that three appointments with
a dietician were not sufficient to improve nutritional status in
underweight lung transplant candidates [13]. An intensive
nutritional programme with extra meals and nutritional supple-
ments during hospitalization in underweight patients with
end-stage lung disease was effective in increasing energy intake
and body weight compared to regular nutritional support [14].
Until now, insight into the nutritional status and the effect of
dietetic intervention in pre- and post-transplant CF patients is
limited. Therefore, the aim of this study was to describe
nutritional status and intake at waiting list entry, subsequent
changes in body weight and FFM before and after LTX, and
survival after LTX using data from out-patient visits.
2. Methods
2.1. Study design
2.1.1. Data at waiting list entry (n = 75 patients)
In the period August 1998–June 2011, 110 CF patients from
different CF centres in the Netherlands had been screened for
LTX. Of these, 98 patients were accepted on the waiting list but
we could retrieve data from 75 CF patients (aged ≥15 years)
from our own patient files. All LTX transplants were performed
in the Lung Transplantation Center, University Medical Center
Utrecht.
2.1.2. Follow-up data (31 of 75 patients)
Of the 75 patients, 51 had an LTX. Unfortunately complete
follow-up data on anthropometry and diet were only available for31 of these patients: 10 died after LTX and 10 patients were
followed for less than 1 year. For the remaining 31 patients we
retrieved anthropometric data at four time points: (1) waiting list
entry (baseline); (2) last outpatient visit pre-LTX; (3) 6–12 months
outpatient visit post-LTX and (4) 18–24 months outpatient visit
post-LTX. Time between the waiting list entry and LTX ranged
between 0 and 81 months. Because no nutritional data were
available for the moment of LTX, we chose the ‘last outpatient
visit pre-LTX’ for time point 2.
2.1.3. Nutritional management
Dietetic care was provided by two registered dieticians to
maintain or improve nutritional status before and after LTX.
During a dietetic consultation patients' nutritional status, dietary
requirements, and dietary intake (from a dietary history) were
assessed. If necessary, use of additional ONS and/or tube feeding
was advised or maintained. Patients were seen as out-patients
every 3–4 months. When patients were unable to maintain body
weight, the daily use of ONS was increased, tube feeding was
started, or the type of tube feeding was changed from normal
(1.5 kcal/ml) to energy enriched (2 kcal/ml). These adjustments
were individual and therefore, they are not reported in this paper.
None of the patients used appetite stimulants.
2.1.4. Clinical measurements
Medical, anthropometric, and nutritional characteristics
were determined at baseline and subsequently every 3–
4 months when the patient had been admitted to the waiting
list. After LTX the patients were seen in the outpatient clinic
every three months the first year, every six months the second
year and once a year after three years.
2.1.5. Medical characteristics
Patient data and surgery-related characteristics were extracted
from electronic medical records.
Pulmonary function was assessed by spirometry (ZAN;
Oberthulba, Germany) and expressed as FEV1% of the
predicted normal Forced Expiratory Volume in 1 s (FEV1).
All FEV1 measurements were performed by the Laboratory
for lung function of the UMCU. Cystic Fibrosis-Related
Diabetes (CFRD) was recorded because of its negative effect
on lung function, particularly in women [15]. Diagnosis of
CFRD was based on the criteria proposed by the American
Diabetes Association 2011 [16].
Pancreatic insufficiency was defined as having insufficient
pancreatic function to achieve normal intestinal absorption of
fat, therefore requiring pancreatic enzyme replacement therapy
(PERT) from an early age.
A High Urgency (HU) status was assigned to patients whose
life expectancy was estimated to be less than three months
according to Eurotransplant guidelines [17].
2.1.6. Anthropometric characteristics
BMI was classified according to the WHO recommendations
[18] and the European Consensus Report for CF [19]:
underweight ≤18.5 kg/m2; normal weight 18.5–24.9 kg/m2 and
overweight 25–29.9 kg/m2. For the 8 adolescents (b18 years)
Table 1
Baseline characteristics of CF transplant candidates at UMCU (n = 75).
Variables Data
Descriptives
Gender, n 41 men, 34 women
Cystic Fibrosis-Related Diabetes, n (%) 47 (63%)
Pancreatic insufficiency, n (%) 73 (97%)
Measurements Median (range)
Age, years 28 (15–53)
Weight, kg 54.4 (40–93)
Height, m 1.69 (1.41–1.89)
BMI, kg/m2 19.2 (15.3–28.4)
FFMI, kg/m2 measured in 65 patients 15.2 (11.1–22.4)
FEV1, % predicted 24.5 (12–37)
FEV1 = Forced Expiratory Volume in 1 s; BMI = BodyMass Index; FFMI = Fat
Free Mass Index.
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proposed by the Netherlands Organisation for Applied Scientific
Research TNO [20]. Measurements of body weight and height
were performed in the Laboratory for lung function of the UMCU
while patients were barefoot and dressed in indoor clothing.
Body composition was routinely measured by Bio Impedance
Analysis (BIA, Bodystat 1500; Bodystat Ltd, Douglas, UK),
while patients were in a fasted state, lying in supine position with
arms apart from the trunk and the legs not touching each other.
Measuring body composition by BIA is a part of our lung
transplantation protocol and is performed by trained personnel
according to standardized methods. BIA is an accepted method
for the assessment of FFM [21] that can be used without
modification in Cystic Fibrosis patients [22]. A low Fat Free
Mass Index (FFMI) was defined as≤14.6 kg/m2 for women and
≤16.7 kg/m2 for men [23].
Weight change (%) was calculated as the changes in body
weight at the follow-up time points relative to the initial body
weight at baseline.
2.1.7. Nutritional measurements and nutritional requirements
Resting Metabolic Rate (RMR) was estimated at baseline by
the formula of Schofield [24] that has been in use in our center
since 1998. Energy requirement was estimated by multiplying
RMR by activity, disease and growth factors and dividing it by
the fat absorption coefficient as follows: RMR × (Activity
Factor + disease factor − 1) × growth factor / (absorption coef-
ficient) [25]. The Activity Factor was 1.1 for limited active
lifestyle, 1.5 for normal active lifestyle and 1.7 for an active
lifestyle. The disease factor was set at 1.3 in the pre-LTX period,
because all patients had a FEV1 b 40% [19]. The growth factor
varied from 1.0 (no growth) to 1.04 (puberty growth spurt). For 9
patients, the fat absorption coefficient was based on measure-
ments of fat absorption during a 72-hour faecal fat test. For the 66
patients for whom no data was available, we used an absorption
coefficient of 0.93 for pancreatic insufficient patients (n = 64)
and 0.97 for pancreatic sufficient patients (n = 2). These
estimates are based on fat digestibility in healthy persons who
excrete less than 7% of the ingested fat with a total daily faecal fat
output of less than 7 g per day [19].
Protein requirements were estimated at 1.5 g protein per kg
actual body weight, which is the recommendation for under-
nourished patients [26].
Energy- and protein intakes were calculated from a dietary
history, a face-to-face interview to determine the usual meal
pattern, taken at baseline. No intake data were available for the
other time points.
2.1.8. Data analyses
Analyses were performed for the whole group (n = 75) and
for men and women separately. Because most data were not
normally distributed, descriptive statistics were expressed as
medians with ranges.
We made the following subgroups: 1. pre-LTX non
survivors; 2. pre-LTX survivors; 3. post-LTX non survivors;
and 4. post-LTX survivors. To test for differences between
subgroups the non-parametric Mann–Whitney U test was usedfor continuous variables and the Chi-square test for dichoto-
mous variables.
To test for differences between time points in the follow-up
data (n = 31), the non-parametric test for dependent variables,
the Friedman test, was used. Statistical significance was defined
as two-tailed p values less than 0.05. The data were analysed
using the SPSS programme for Windows (version 17.0; SPSS
Inc, Chicago).
3. Results
3.1. Waiting list entry (n = 75)
3.1.1. Study population at baseline
A total of 75 patients (41 men) were included (Table 1), with
a median age of 28 years (range: 15 to 53 years). The median
FEV1 was 25% of predicted (range: 12 to 37% of predicted).
CFRD was diagnosed in 63% of the patients and was more
pronounced in women (p = 0.005). Pancreatic insufficiency
was diagnosed in all but 2 patients. Of the 75 patients who were
admitted to the waiting list for LTX, 51 patients survived long
enough to undergo LTX. Seventy-five percent of these patients
had an HU status before surgery.
3.1.2. Anthropometrics
The median BMI at baseline was 19.2 kg/m2 (range: 15.3 to
28.4 kg/m2) with 29 patients below ≤18.5 kg/m2, 45 patients
between 18.5 and 24.9 kg/m2 and 1 patient with a BMI
≥25 kg/m2. FFMI measurements were available for 65
patients. Their median FFMI was 15.2 kg/m2 (range: 11.1 to
22.4 kg/m2) with 24 men ≤16.7 kg/m2 and 15 women
≤14.6 kg/m2. Undernourishment based on BMI was 39%
(29/75) against 60% (39/65) based on FFMI. All patients with
a low BMI also had a low FFMI but a ‘normal’ BMI was
almost equally associated with a low or normal FFMI (Fig. 1).
3.1.3. Nutritional requirements, intake and interventions
The median energy intake estimated from the dietary history
at baseline was 2800 kcal (range 1570–4700). This was close
to the estimated median energy requirement of 2600 kcal.
Table 2
Nutritional requirements and intake (means and ranges) of 74 CF patients at
waiting list entry (1 patient was screened in another hospital, data unavailable).
Men (n = 40) Women (n = 34)
Nutritional requirements
Estimated Resting Metabolic
Rate (kcal/day)
1600 (1320–1960) 1280 (1110–1460)
Energy requirement, kcal/day 3100 (2160–4050) 2410 (1740–3240)
Protein requirement, g/day 92 (62–140) 78 (60–110)
Nutritional intake a
Energy intake
(%energy requirement)
101 (55–160) (n = 38) 101 (63–164) (n = 33)
Protein intake
(%protein requirement)
130 (73–253) (n = 33) 130 (80–220) (n = 31)
a Intake data not complete for all 74 patients.
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below recommendation.
Protein requirements were easier to meet; only 19% of the men
and 20% of the women did not meet the protein requirements of
1.5 g/kg/day. Men and women were not different in achieving
energy and protein requirements (Table 2).
For 74 patients we had information on the use of nutritional
supplements at screening (missing data for 1 patient who was
screened in another hospital). Of these, 63 patients (85%) used
ONS and/or tube feeding in addition to their diet. For 6 men and 6
women the nutritional intervention was aimed at increasing rather
than preserving intake. In these patients, mean weight increase
during waiting list time was 2.2 kg. Weight increase in patients
who were advised to maintain body weight was 2.8 kg
(difference not significant). Tube feeding (17 out of 25 patients)
was mainly through Percutaneous Endoscopic Gastrostomy
(PEG) feeding tubes. Energy intake as a percentage of energy
requirement was 116% for patients with a screening BMI ≤18.5
and 102% for patients with a BMI N18.5 (p = 0.051).
3.1.4. Baseline nutritional status and survival
We investigated whether a low BMI or FFMI at waiting list
entry was predictive of survival. From those who died before
transplantation (n = 9), 67% (n = 6) had a BMI ≤18.5 kg/m2
and 78% (n = 7) had a low baseline FFMI (men ≤16.7 and
women ≤14.6 kg/m2). From those who died after transplanta-
tion (n = 10), 40% (n = 4) had a low BMI and 60% (n = 6) had
a low baseline FFMI. Patients who survived transplantation
(n = 41) had a somewhat better nutritional status: 34% (n = 14)
had a BMI ≤18.5 kg/m2 and 40% (n = 16) had a low FFMI
(Fig. 2). However, medians of BMI and FFMI were not
significantly different between the 41 LTX survivors and the 10
LTX non-survivors (data not shown).
3.2. Follow up data on nutritional status after LTX (n = 31)
3.2.1. Study population
Of the 51/75 patients who underwent LTX, follow-up data
about nutritional status was available for 31 patients (Fig. 3).
We were unable to retrieve follow up data for 20 other patients:BMI18.5-24.9
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Fig. 1. Number of patients with low or normal Fat Free Mass Index (FFMI)
according to Body Mass Index (BMI) groups (underweight, normal and
overweight). The table includes 65 patients because FFMI data were missing in
10 patients.10 had died within a year after LTX and 10 had a follow up of
less than one year after LTX. These patients were excluded
from the data analysis on nutritional status.3.2.2. Anthropometrics
There was no significant improvement in BMI or FFMI
between waiting list entry and the last visit before transplantation,
although the number of patients with a BMI ≤18.5 kg/m2
reduced from 13 (42%) to 8 (26%) (p = 0.025) (Table 3). After
LTX, BMI and FFMI increased significantly both for men and
women compared to the data at baseline (Table 3). Body weight
after LTX increased significantly compared to body weight
pre-LTX. Themean weight gain at 18–24 months post-LTX, as a
proportion of initial body weight, was 11% for men and 8% for
women (respectively p = 0.001 and p = 0.034). Strongest
increases in body weight were seen in men who started with
underweight (Fig. 3): at 6–12 and 18–24 months post-LTX this
difference between men was statistically significant (p = 0.001
and p = 0.015). For women weight gain during follow-up was
less affected by initial BMI.*
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Fig. 2. Percentage of patients with a low Body Mass Index (BMI) or low Fat Free
Mass Index (FFMI) according to LTX status: †pre-LTX = death before LTX,
†post-LTX = death after LTX (within 24 months), √ post-LTX = survived after
LTX. Asterisk (*) indicates significant difference from †pre-LTX group. Not in
the figure: 15 patients who were still waiting for LTX (making a total of 75
patients).
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Fig. 3. Pre- and post-LTX mean weight expressed as percentage from baseline in men and women with low or normal BMI at four time points (total n = 31.).
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The type of feeding was known for 20 of the 22 men and 8 of
the 9 women. In men, the use of ONS and/or tube feeding
decreased significantly during follow up from 17 to 9 (p = 0.001).
In women this number declined from 8 to 3 (p = 0.025).
Although overall nutritional status improved, PEG feeding was
still necessary in 5 patients at 18–24 months after LTX.
4. Discussion
This study was performed to describe changes in nutritional
status in pre- and post-LTX CF patients, and how this relates to
dietetic interventions and survival. At the entrance of the LTX
programme, most patients had a long history of dietetic care
and were familiar with nutritional support. However, almost
50% of the patients did not meet the recommended intake level
of energy at baseline and 36% of the patients were underweight
based on their BMI. Nutritional support during the pre-LTX
period was unable to improve body weight or FFM, although
further deterioration was prevented. After LTX, bodyweight,
BMI and FFMI improved gradually.
Our study was limited by its retrospective approach; not all
data could be retrieved. For 12 LTX patients who died within
one year after transplantation no medical records were
available. It would have been interesting to know their baseline
BMI and FFMI. We assume that the use of electronic patient
files will facilitate follow-up studies in the future. Secondly, we
only used data from the outpatient clinic. Sometimes patients
are hospitalized for more than 6 months and this may have an
impact on bodyweight and composition before LTX.
Compared to other studies in pre- and post-LTX patients, our
study population had lower values for body weight, BMI and
FFMI [17,23,28,29]. This may be explained not only by
treatment differences, but also by differences in study population
(other LTX-studies included populations with chronic obstructive
pulmonary disease, emphysema and bronchiectasis) ordifferences in cut off points used to classify underweight
(e.g. BMI varying from b17 to b21 kg/m2). In our data a weak
association was suggested between low baseline FFMI and
survival, as was seen in earlier studies [2,3]. Although this
appears to be plausible, follow up data of larger study
populations are needed to confirm this.
European and Dutch nutritional guidelines recommend an
intake of 120–150% of the estimated average requirement for
energy for CF individuals compared to healthy peers [19]. In our
pre-LTX population 48% failed to achieve recommended energy
intake and 20% failed to achieve recommended protein intake.
This percentage is lower than described by White et al. where
72% of the general CF population failed to achieve recommended
energy- and protein intake [31]. However, this may be due to
differences in absorption factor, Activity Factor and/or disease
factor that are used to calculate total energy expenditure.We used
an absorption factor of 0.93 for pancreatic insufficient patients
but factors between 0.85 and 0.9 and thus higher energy
requirements have been proposed [32]. Moreover, the disease
factor was now set at 1.3 for all patients but this may be too low
during periods of respiratory tract infection. It is therefore
possible that we underestimated energy requirements, which
might explain why improvement of BMI and FFMI was not seen
pre-LTX. To our knowledge, only one study described the dietary
intake of pre- and post-LTX patients with CF, suggesting that
despite a high caloric intake these patients remain malnourished
before LTX while post-LTX they became well-nourished despite
a drop in caloric intake [29]. Future research should explore
actual energy demands in pre-and post-LTX patients with CF
using measured instead of calculated energy expenditure data.
During the waiting list period we advised ONS and/or tube
feeding in patients who were unable to maintain or improve
body weight. Kalnins et al. compared the effects of oral dietary
supplements with dietary counselling on energy intake and
nutritional status in malnourished CF patients, and reported that
over a 3-month period neither sip feeding alone nor dietary
Table 3
Pre- and post-LTX follow-up longitudinal characteristics of 31 CF patients, separated for men and women a.
Time points 1 waiting list entry 2 last outpatient clinic
visit pre-LTX
3 outpatient clinic visit
6–12 months post-LTX
4 outpatient clinic visit
18–24 months post-LTX
MEN (n = 22)
Medical and anthropometric variables
Age, year 30 (16–53) 30 (17–53) c 29 (18–54) d 32 (19–55) d
FEV1, % predicted 22 (14–35) (n = 21) 20 (13–35) c (n = 21) 76 (23–99) d 83 (12–111) d
Weight, kg 61 (42–78) 59 (45–77) 60 (49–79) c 67 (48–82) d
Weight change, % b 0 (−6 to +22) 6 (−13 to +31) 14 (−16 to +48)
BMI 19.2 (15.3–23.8) 19.6 (16.1–22.9) 20.3 (17.3–22.9) c 21.7 (16.5–24.8) d
BMI ≤ 18.5, n (%) 9 (41) 6 (27) 3 (14) c 4 (18)
FFMI 16.1 (11.1–19.4) (n = 17) 16.4 (12.5–18.6) (n = 20) 18.0 (15.3–19.7) c (n = 20) 18.0 (14.1–20.6) c (n = 20)
% FFMI ≤16.7 kg/m2, n (%) 12 (71) 12 (60) 6 (30) c 4 (20) c
WOMEN (n = 9)
Medical and anthropometric variables
Age, year 22 (16–48) 25 (16–49) c 26 (17–50) c 27 (17–51) c
FEV1, % predicted 23 (17–28) 22 (17–29) 80 (58–98) c 78 (71–101) c
Weight, kg 54 (40–64) 55 (40–63) 57 (39–68) c 57 (43–78) c
Weight change, % b 0 (−6 to +13) 6 (−3 to +25) 8 (−5 to +22)
BMI 18.6 (16.0–21.7) 19.7 (16.0–21.3) 19.8 (15.6–24.1) c 20.4 (17.2–25.5) c
BMI ≤ 18.5, n (%) 4 (44) 2 (22) 2 (22) 1 (11)
FFMI 14.8 (12.7–16.7) (n = 7) 14.9 (13.4–16.7) (n = 7) 16.3 (13.3–17.3) c (n = 8) 16.1 (14.1–18.4) c
FFMI ≤14.6 kg/m2, n (%) 3 (43) 3 (43) 2 (25) 3 (33)
Definition of abbreviations: FEV1 = Forced Expiratory Volume in 1 s; BMI = Body Mass Index; FFMI = Fat Free Mass Index.
a Data are presented as median (min–max) or n (%), n = number of persons.
b Percentage weight change compared to weight at baseline.
c p b 0.05, Friedman test between data at time point 2, 3 or 4 vs. time point 1.
d p ≤ 0.001, Friedman test between data at time point 2, 3 or 4 vs. time point 1.
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half of the patients used ONS at baseline. ONS is meant to be
an addition but may replace dietary intake when appetite is
worsened due to a disease. In that case advising ONS may have
the opposite of the desired effect. PEG tube feeding may not
have this effect. In fact, it was shown to improve nutritional
status in patients with CF and with end-stage lung disease in
two studies [34,35]. Possibly, more aggressive nutritional
therapy with PEG tube feeding may be necessary to stimulate
nutritional rehabilitation before LTX. Whether this improves
survival needs to be evaluated.
After transplantation significant improvements in weight,
BMI and FFMI were found for both men and women. A limited
number of studies consistently found that body weight
improved after LTX [28,30]. Singer et al. found that weight
gain was greatest in patients with CF and bronchiectasis
compared to other LTX groups [28]. The weight gain in our
study could have been overestimated because some of the
patients had their LTX before the age of 18. At waiting list
entry eight patients were between 15 and 18 years old. Age
related increases in weight and BMI could appear as successful
nutritional interventions and therefore overestimate the effect of
dietetic intervention. However, we expect that this effect only
marginally influenced our analyses, because only 4 of these
young patients were included in the nutritional follow-up
analyses. In accordance with our findings, Habedank found that
weight gain was the highest in underweight patients [30]. In our
study, this was more pronounced in men than in women.
Possibly women feel more comfortable with their lower bodyweight. This phenomenon is also described by Abbott et al.
who found that women with CF reported more dieting
behaviour, greater preoccupation with food and more pressure
from others to eat than CF males [36].
Although on average body weight increased after LTX, we
observed a wide variation in weight change between patients.
Postoperative weight loss may be explained by specific
complications during the clinical course after LTX. One
patient required re-transplantation, another one had a severe
infection, and in one patient the PEG tube was not accessible.
In other words, several causes may lead to unwanted weight
loss. Weight gain post-LTX may have been affected by
corticosteroid therapy, which was administered to all patients
after LTX. However, we expect this effect to be minimal,
because after 7–12 months daily prednisone dose was
minimized to 10 mg in the majority of the patients. Various
studies have shown that the relation between corticosteroid
dose and weight gain in transplant populations is not
significant [27,37,38].
In conclusion, a low BMI and especially a low FFMI at
waiting list entry appear to impair survival in CF patients who
are LTX candidates. Patients maintained a low body weight
before LTX despite the use of additional ONS and/or tube
feeding. After LTX weight gain is achieved, and more
pronounced in patients who start with underweight. More
research is needed on the impact of nutritional status on
prognosis, on the specific nutritional requirements at several
stages of the treatment process and on the effectiveness of
several nutritional support measures.
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